OptimizeRx (OTCMKTS:OPRX) had its price target lifted by equities research analysts at Lake Street Capital to $2.50 in a research report issued on Wednesday, February 28th, The Fly reports. The firm presently has a “buy” rating on the technology company’s stock. Lake Street Capital’s price target indicates a potential upside of 59.24% from the stock’s previous close.
OptimizeRx stock traded up $0.02 during trading on Wednesday, hitting $1.57. 16,350 shares of the stock traded hands, compared to its average volume of 104,891. The firm has a market cap of $46.91, a price-to-earnings ratio of -22.43 and a beta of 0.78. OptimizeRx has a one year low of $0.63 and a one year high of $1.66.
OptimizeRx (OTCMKTS:OPRX) last announced its quarterly earnings results on Tuesday, February 27th. The technology company reported ($0.01) EPS for the quarter. OptimizeRx had a negative net margin of 17.36% and a negative return on equity of 32.66%. The company had revenue of $4.01 million during the quarter.
OptimizeRx Corporation is a technology solutions company. The Company focuses on the healthcare industry. The Company connects patients, physicians and pharmaceutical manufacturers through technology. The Company’s solutions provide pharmaceutical manufacturers a direct to physician channel for communicating and promoting products.
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.